- Cart 0
- English
Breakthrough Discovery: Nuclear PTGES3 Function Drives Hepatocellular Carcinoma Progression—Molecular Biomedicine Study Validates Mechanism
April 14, 2026
Clicks：74
Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer-related mortality globally, presents a persistent therapeutic challenge due to the synergistic interplay between tumor proliferation and the immunosuppressive microenvironment. A recent study published in Molecular Biomedicine has, for the first time, elucidated the non-canonical nuclear function of PTGES3 — simultaneously regulating intrinsic tumor growth and extrinsic immune remodeling via the SP1/TGF-β axis, thereby providing a novel therapeutic target for HCC treatment. Notably, the critical PTGES3 protein purification experiments in this study relied on Absin's rProtein A/G Magnetic IP/Co-IP Kit (Cat. No.: abs9649), which provided essential technical support for mechanistic validation.
Publication Information
Title: Nuclear prostaglandin E synthase 3 promotes hepatocellular carcinoma growth with immunosuppressive macrophage polarization via the SP1/TGF-β axis
Journal: Mol Biomed. (IF=10.1)
DOI: https://doi.org/10.1186/s43556-026-00431-6
Absin Product: Immunoprecipitation (IP/Co-IP) Kit (Magnetic Beads) (Cat. No.: abs9649)
I. Research Strategy: Decoding the "Dual Identity" of PTGES3 Through Layered Investigation
The research team employed a multi-dimensional validation framework encompassing "clinical - cellular - animal - molecular" approaches to progressively uncover the mechanistic role of PTGES3 in HCC:
- Clinical Correlation Validation: Analysis of five independent public datasets (comprising 818 paired samples) and 87 paired clinical tissue microarrays confirmed that PTGES3 is highly expressed in HCC tissues and represents an independent risk factor for poor prognosis.
- Functional Phenotypic Screening: Gain-of-function and loss-of-function experiments at the cellular level validated the promoting effects of PTGES3 on HCC cell proliferation, migration, and anti-apoptotic capacity.
- In Vivo Model Validation: Utilizing a hepatocyte-specific PTGES3-silenced DEN-induced HCC mouse model, the tumor-promoting function of PTGES3 was confirmed in an immunocompetent environment.
- Immune Microenvironment Analysis: Combining single-cell RNA sequencing (scRNA-seq) and co-culture systems, the regulatory effects of PTGES3 on tumor-associated macrophage (TAM) polarization were investigated.
- Molecular Mechanism Elucidation: Through CUT&Tag, ChIP-qPCR, EMSA, and other techniques, the downstream targets and regulatory pathways of PTGES3 were identified.
The research logic is clearly structured, progressing from clinical observations to molecular mechanisms, with each validation step providing robust support for the final conclusions.
II. Core Research Findings: The "Nuclear Functional Revolution" of PTGES3 and Its Dual-Drive Mechanism
1. Clinical Value: PTGES3 as a "Prognostic Alert Signal" for HCC
The study demonstrated that both mRNA and protein levels of PTGES3 were significantly elevated in HCC tissues compared to adjacent non-tumorous tissues (Fig. 1 in the original article). Patients with high PTGES3 expression exhibited significantly shortened disease-free survival (DFS) and overall survival (OS) (DFS: P=0.024; OS: P=0.018). Multivariate Cox regression analysis confirmed that high PTGES3 expression is an independent risk factor for poor prognosis (aHR=2.37, 95% CI: 1.206-4.657), suggesting its potential as a novel biomarker for HCC prognostic assessment.
2. Functional Validation: The Dual Role of PTGES3 in "Proliferation Promotion" and "Immune Modulation"
Intrinsic Tumor Drive: PTGES3 silencing reduced HCC cell proliferation by approximately 40%, decreased migratory capacity by 53%, and increased apoptosis rates by nearly 2-fold (Fig. 2 in the original article); furthermore, PTGES3 promotes tumor progression through activation of the PI3K/AKT/mTOR signaling pathway, an effect that can be reversed by the mTOR inhibitor rapamycin (Fig. 3 in the original article).
Fig. 2.
PTGES3 promotes HCC cell proliferation, migration, and survival in Huh7 cells.
| Panel | Experimental Content | Key Findings |
|---|---|---|
| a | Cell viability assays (MTT) | PTGES3 knockdown/overexpression in Huh7 cells at 48 h (n=3; n=8 technical replicates) |
| b | Colony formation assays | Representative images and quantification of colonies (n=3) |
| c | Migration assays | Wound closure at 0 and 48 h, scale bars 100 μm (n=3) |
| d | Apoptosis analysis | Flow cytometry plots, Annexin V⁺/7-AAD⁻ and Annexin V⁺/7-AAD⁺ (n=4) |
Statistical analysis: One-way ANOVA with Dunnett's/Tukey's post hoc test, or two-tailed unpaired Student's t-test. ** P<0.01, *** P<0.001, **** P<0.0001
Fig. 3.
PTGES3 activates the PI3K/AKT/mTOR signaling pathway to promote HCC progression.
| Panel | Experimental Content |
|---|---|
| a | Volcano plot: DEGs in Huh7 cells following PTGES3 knockdown (n=3; |log₂FC|>0.5, adjusted P<0.05) |
| b | KEGG pathway enrichment: PI3K/AKT pathway as primary downstream target |
| c | Western blot: PI3K, p-AKT, t-AKT, p-mTOR, t-mTOR, p-P70S6K, t-P70S6K, p-4EBP1, t-4EBP1 (n=3) |
| d-f | Rescue assays: MTT, wound closure, colony formation with Rapamycin (100 nM) treatment (n=3) |
Statistical analysis: Wald test with Benjamini–Hochberg correction, or Two-way ANOVA with Tukey's post hoc test. ** P<0.01, *** P<0.001, **** P<0.0001
Immune Microenvironment Remodeling: PTGES3 silencing significantly reduced TAM infiltration (15.8% vs 23.4%) and inhibited M2 polarization (Fig. 5 in the original article). The core mechanism involves regulation of TGF-β secretion rather than the classical PGE2 pathway.
Fig. 5.
PTGES3 drives M2 macrophage polarization in the HCC microenvironment via the TGF-β axis.
| Panel | Experimental Content |
|---|---|
| a-c | scRNA-seq: t-SNE visualization, cellular composition, M1/M2 polarization signatures (n=3) |
| d | IF images: CD206 (red) and DAPI (blue) in mouse HCC tissues, scale bars 20 μm (n=6) |
| e | FACS: CD14⁺CD163⁺ M2 and CD14⁺CD86⁺ M1 macrophages in Huh7/M0 co-culture |
| f-i | ELISA: PGE2 (n=6), TGF-β in hepatic tissues (n=4) and cell supernatants (n=3) |
| j | Rescue assay: CD163 Western blot with exogenous TGF-β (10 ng/mL) (n=3) |
Statistical analysis: Wilcoxon rank-sum/signed-rank test, two-tailed unpaired Student's t-test, or One-way ANOVA with Tukey's post hoc test. * P<0.05, *** P<0.001, **** P<0.0001; ns, not significant
3. Mechanistic Breakthrough: Nuclear PTGES3 Achieves Dual Regulation Through the SP1/TGF-β Axis
The most critical innovation of this study lies in the discovery of the non-canonical nuclear function of PTGES3:
PTGES3 can translocate into the nucleus and directly bind to the G-rich motif of the SP1 promoter (validated through EMSA and CUT&Tag, Fig. 6 in the original article), transcriptionally activating SP1 expression.
Fig. 6.
Nuclear PTGES3 directly binds and transcriptionally activates SP1.
| Panel | Experimental Content |
|---|---|
| a | Venn diagram: Intersection of PTGES3-bound genes (CUT&Tag) and TGFB1 transcriptional regulators (TRRUST v2) |
| b | IGV tracks: PTGES3 enrichment at SP1 promoter region |
| c | Motif analysis: G-rich motif sequence identification |
| d | EMSA: Biotinylated SP1 promoter probes with purified PTGES3 protein (Shift/Competition assays) |
| e | ChIP-qPCR: PTGES3 recruitment to SP1 promoter (n=3) |
| f | Dual-luciferase reporter: WT vs Mut SP1 promoter (n=3) |
| g-h | qPCR and Western blot: SP1 mRNA and protein levels (n=3) |
| i | ELISA: TGF-β secretion with SP1 knockdown rescue (n=4) |
| j-l | Rescue assays: siSP1, ITD-1 (TGFBR inhibitor, 5 μM), 17-AAG (HSP90 inhibitor, 0.5 μM) |
Statistical analysis: Two-tailed unpaired Student's t-test, Two-way ANOVA with Šídák's/Tukey's post hoc test. ** P<0.01, *** P<0.001, **** P<0.0001; ns, not significant
Activated SP1 further promotes TGF-β secretion, forming a dual signaling loop: ① Autocrine loop (TGF-β→TGFBR→PI3K/AKT/mTOR) maintains tumor proliferation; ② Paracrine loop (TGF-β→TAM M2 polarization) constructs an immunosuppressive microenvironment (Fig. 7 in the original article).
Fig. 7.
Schematic of the nuclear PTGES3/SP1/TGF-β signaling axis.
This model illustrates that PTGES3 translocates to the nucleus and specifically binds to the G-rich motif of the SP1 promoter, driving SP1 transcription. Upregulated SP1 promotes TGF-β secretion, which drives HCC progression through two parallel signaling loops:
- Autocrine Loop: Secreted TGF-β binds to TGFBR on HCC cells, triggering phosphorylation of the PI3K/AKT/mTOR cascade to sustain tumor proliferation and migration. This axis was functionally validated using specific inhibitors ITD-1 (targeting TGFBR) and rapamycin (targeting mTOR).
- Paracrine Loop: Secreted TGF-β acts on tumor-associated macrophages (TAMs), inducing CD206⁺ M2 polarization and establishing an immunosuppressive microenvironment.
III. Critical Tool: Absin abs9649 Facilitates Core Mechanistic Validation
In the critical experiments elucidating PTGES3 binding to the SP1 promoter, the research team faced a central challenge: obtaining high-purity, active recombinant PTGES3 protein — a prerequisite for successful EMSA experiments.
Core Function of abs9649:
The study explicitly employed Absin's rProtein A/G Magnetic IP/Co-IP Kit (Cat. No.: abs9649) for the purification of recombinant PTGES3 protein ("Materials and methods-EMSA" section in the original article). This kit ensured experimental success through the following advantages:
- High-Purity Enrichment: Through dual Protein A/G affinity chromatography technology, the kit efficiently captures target proteins while removing contaminating proteins, ensuring PTGES3 protein purity meets EMSA experimental requirements.
- Activity Preservation: Mild elution conditions maintain the native conformation and DNA-binding activity of PTGES3, enabling specific binding to SP1 promoter probes and formation of clear shift bands (Fig. 6d in the original article).
- Operational Convenience: The magnetic bead-based design simplifies the purification workflow, reduces protein loss, and improves experimental efficiency, ensuring reproducibility for subsequent EMSA experiments.
Leveraging the highly active PTGES3 protein purified with abs9649, the research team successfully validated through EMSA experiments that PTGES3 can directly bind to the G-rich motif of the SP1 promoter, and that this binding is sequence-specific (wild-type probes can compete for binding, whereas mutant probes show no competitive effect). This finding serves as the central supporting evidence for the entire molecular mechanism.
IV. Research Significance and Product Value Outlook
This study not only reveals the potential of PTGES3 as a novel therapeutic target for HCC, providing new insights for combined targeted therapy and immunotherapy, but also demonstrates the critical supporting role of high-quality experimental tools in scientific breakthroughs.
Absin abs9649, as a mature protein purification tool, has been widely applied in critical experiments including IP, Co-IP, and protein purification. Its reliability and stability have been validated in multiple high-impact studies. For researchers engaged in transcriptional regulation, protein-protein interactions, and related fields, abs9649 provides efficient and stable experimental solutions, facilitating the smooth execution of mechanistic validation experiments.
In the future, as PTGES3-related targeted drugs continue to be developed, such core tools from basic research will continue to support translational medical research, and Absin will remain committed to empowering more breakthrough discoveries in life sciences through high-quality reagents.
For product details or related application cases of abs9649, please visit www.absin.net or contact our technical support team to obtain customized experimental solutions.
Contact Absin
Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.
| Absin Bioscience Inc. worldwide@absin.cn |
 Follow us on Facebook: Absin Bio |